Related Experiment Video
Updated: Nov 23, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable
Musalula Sinkala1, Panji Nkhoma2, Nicola Mulder3
1University of Cape Town, Cape Town, South Africa. smsinks@icloud.com.
Abstract:
The mitogen-activated protein kinase (MAPK) pathways are crucial regulators of the cellular processes that fuel the malignant transformation of normal cells. The molecular aberrations which lead to cancer involve mutations in, and transcription variations of, various MAPK pathway genes. Here, we examine the genome sequences of 40,848 patient-derived tumours representing 101 distinct human cancers to identify cancer-associated mutations in MAPK signalling pathway genes. We show that patients with tumours that have mutations within genes of the ERK-1/2 pathway, the p38 pathways, or multiple MAPK pathway modules, tend to have worse disease outcomes than patients with tumours that have no mutations within the MAPK pathways genes. Furthermore, by integrating information extracted from various large-scale molecular datasets, we expose the relationship between the fitness of cancer cells after CRISPR mediated gene knockout of MAPK pathway genes, and their dose-responses to MAPK pathway inhibitors. Besides providing new insights into MAPK pathways, we unearth vulnerabilities in specific pathway genes that are reflected in the re sponses of cancer cells to MAPK targeting drugs: a revelation with great potential for guiding the development of innovative therapies.
Insights
Mutations in mitogen-activated protein kinase (MAPK) pathways are linked to poorer cancer outcomes. Targeting these MAPK pathway genes reveals vulnerabilities, offering potential for new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mitogen-activated protein kinase (MAPK) pathways regulate critical cellular functions.
- Aberrations in MAPK pathway genes, including mutations and transcriptional variations, are implicated in cancer development.
Purpose of the Study:
- To identify cancer-associated mutations within MAPK signaling pathway genes across a large cohort of human tumors.
- To investigate the correlation between MAPK pathway mutations and patient disease outcomes.
- To explore the relationship between MAPK pathway gene fitness, CRISPR-mediated knockout, and drug response.
Main Methods:
- Genome sequencing of 40,848 patient-derived tumors across 101 cancer types.
- Analysis of mutations in key MAPK pathway genes (ERK-1/2, p38).
- Integration of large-scale molecular datasets, including CRISPR screening and drug response data.
Main Results:
- Patients with MAPK pathway gene mutations exhibited significantly worse disease outcomes compared to those without.
- CRISPR-mediated knockout of MAPK pathway genes revealed cancer cell fitness dependencies.
- A correlation was established between gene knockout fitness and sensitivity to MAPK pathway inhibitors.
Conclusions:
- MAPK pathway mutations are significant prognostic markers in various cancers.
- Specific MAPK pathway genes present vulnerabilities exploitable by targeted therapies.
- Findings provide a basis for developing novel MAPK-targeted cancer treatments.
More Related Videos
Related Concept Videos
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:07MAPK Signaling Cascades
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:18Cancer
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...